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ABSTRACT 
Nanotechnology based drug delivery system have shown to improve solubility, rate of dissolution and oral bioavailability of poorly 
water soluble drugs. Present study is aimed to develop Nebivolol loaded chitosan nanoparticles (NB-CS-NPS) for enhancing its oral 
bioavailability. The NPs optimized by implementation of Taguchi orthogonal array design. The optimized batch (NB-CS-NPS-1) of 
NPs exhibited average particle size of 91 ± 45 nm , entrapment efficiency of 70.98% and with zeta potential of + 36.8mV ± 2mV and 
stability at 25 ± 2∘C/ 60 ± 5% RH. The in vitro release data studies have shown improved solubility and oral bioavailability of 
Nebivolol. 
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INTRODUCTION:  
Poor aqueous solubility of the pharmaceutical entity is 
one of the major limitations in successful oral drug 
delivery.  Among various approaches available to 
improve problems related to poor solubility of drugs, 
nanotechnology based drug delivery system offers 
advantages to overcome the problems associated with 
the oral delivery of these drugs. Nanoparticles exhibit 
increased surface area which results in increased 
dissolution rate, enable to control pharmacokinetic 
properties of a dosage form, ease of administration and 
readily penetrate through capillary and epithelial 
membrane, which permits an effective oral delivery of 
poorly soluble drugs. The present study is aimed to 
develop Chitosan nanoparticles containing poorly 
soluble antihypertensive drug, Nebivolol, in order to 
improve its solubility and oral bioavailability. 
MATERIAL AND METHODS: 
Material  
Chitosan (CS) was obtained as gift sample from Central 
Institute of Fisheries Technology (Cochin, India). 
Sodium tripolyphosphate (TPP) was procured from 
Loba Chemie Pvt. Ltd. (Mumbai, India). Nebivolol 
(NEB) was obtained as a gift sample from Lupin Ltd. 
(Pitahmpur, Indore, India). All other chemicals and 
reagents were of analytical grade. 
Methods  
The NB-loaded NPs were fabricated according to the 
procedure reported. Chitosan solutions of different 
concentrations were prepared by dissolving chitosan in 
1% aqueous acetic acid solution. Tween 80 (2% v/v) 
was added as a surfactant to it under constant stirring at 
room temperature. Subsequently, drug (2.5%) was 
dissolved in dichloromethane (2.5 mL), and then this oil 
phase was added drop wise to the aqueous phase. This 
addition was accompanied by continuous stirring for 5 
minutes at different speeds using high speed 
homogenizer. Finally, 10ml TPP solution of different 
concentration was added drop wise into o/w emulsion to 
induce cross-linking of the particles under magnetic 
stirring at 500 rpm. The stirring was continued to ensure 
complete evaporation of dichloromethane, it was kept 
overnight at 40°C. Nanoparticles were collected by 
centrifugation at 15,000 rpm for 25 minutes at 20°C 
using cooling centrifuge. The supernatant was subjected 
for the determination of presence of free Nebivolol by 
UV spectrophotometer (UV 1700, Shimadzu, Japan). 
Optimization of nanoparticles By Taguchi 
orthogonal array design  
The optimization of the NPs formulation was carried out 
by using Taguchi orthogonal array design. Based on the 
number of factors and their levels, L9 (3
4)
 orthogonal 
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array was employed. Four factors i.e. polymer 
concentration (%w/v), TPP concentration (%w/v), CS: 
TPP ratio (%v/v) and stirring speed (rpm) were selected 
and assigned three levels i.e. low, medium and high. The 
optimum conditions with optimal desirability were 
determined with the minimum possible effect of the 
noise factor. 
Characterization of nanoparticles 
Transmission electron microscopy (TEM) 
The morphology of nanoparticles was observed under 
transmission electron microscopy (Morgagni 268D 
TEM instrument, AIIMS, New Delhi). The diluted and 
filtered sample was plunged on the 200 mesh carbon 
coated copper grids and was allowed to dry completely 
in the air. After drying, sample grid was loaded onto a 
specimen holder and viewed under a transmission 
electron microscope. 
Drug-excipient compatibility studies by differential 
scanning calorimeter (DSC) 
The nanoparticles and drug powder were subjected to 
previously calibrated differential scanning calorimeter 
(DSC-60, Shimadzu Corporation, Japan). The sample 
was sealed hermetically in an aluminum pan and 
subjected to nitrogen gas at a flow rate of 50 ml/min. 
The thermograms were obtained at scanning temperature 
range of 50-250°C at a heating rate of 10°C/min. DSC 
thermograms were recorded for CS, NEB and NEB-CS 
NPs. 
Measurement of particle size, polydispersity index (PDI) 
and zeta potential (ZP) of nanoparticles 
Particle size, PDI and ZP of nanoparticles were 
determined through Dynamic light scattering (DLS) 
analysis with Malvern Zetasizer Nano S (Malvern, UK). 
About 100  L of the prepared nanoparticles dispersion 
was diluted to 5ml with double distilled water and 
analyzed with zetasizer. The analysis was performed in 
triplicate at a temperature of 25 
 
C.  
Determination of entrapment efficiency  
The entrapment efficiency of the nanoparticulate 
formulation was determined in triplicate using ultra-
violet spectrophotometer.  The nanoparticles were 
separated from the aqueous medium (containing 
unentrapped NEB) by centrifugation at 25000 rpm for 
30 min (REMI CPR-24 Plus, Remi Elektrotechnick, 
India). The supernatant was diluted with an appropriate 
amount of 0.1 N HCl and analyzed for the amount of 
unentrapped drug by UV-Visible spectrophotometer 
(Shimadzu 1700, Japan) at 285 nm.  
The percentage drug encapsulated was determined by 
following the formula: 
                           
                       
          
      
In vitro drug release studies 
The in-vitro drug release of nanoparticles was studied 
by using dialysis membrane (Himedia, India) with a 
pore size of 2.4nm and molecular weight cut-off 
between 12,000–14,000 in phosphate buffer saline 
(PBS) pH 7.4 at 37 ± 2˚C. Dialysis membrane was 
soaked overnight in double distilled water prior to the 
release studies. The drug-loaded nanoparticles were 
placed into a dialysis bag and were suspended in a 
beaker containing PBS under magnetic stirring while 
maintaining perfect sink condition. Aliquot samples 
were withdrawn periodically and replaced with fresh 
dissolution medium in the same volume. The amount of 
drug released was analyzed spectrophotometrically at 
285 nm for NEB. For comparative purpose, the In vitro 
drug release study was also performed for the marketed 
formulation using USP paddle type dissolution 
apparatus. 
Accelerated stability studies 
Nebivolol loaded nanoparticles were subjected to a 
stability testing for three months as per International 
Conference on Harmonisation (ICH) Q1A (  2) 
guidelines. Freshly prepared nanoparticles were 
transferred to 5 ml glass vials sealed with plastic caps 
and were kept in stability chamber (Remi SC-12 Plus, 
Remi Instruments. Ltd. Mumbai, India) maintained at 25 
± 2∘C/60 ± 5%RH for a period of total 3 months.  The 
formulations were monitored for changes in particle 
size, zeta potential and entrapment efficiency. 
RESULT AND DISCUSSION: 
Particle size analysis by transmission electron 
microscopy (TEM) 
The structural morphology of nanoparticles was 
examined by TEM. TEM image showed that the 
optimized formulation is nearly spherical in shape and a 
smooth surface distributed throughout the sample 
(Figure 1).  
 
Figure 1: Drug-excipient compatibility studies 
The pure drug, Nebivolol, showed a sharp endothermic 
peak at 221°C corresponding to its melting temperature. 
Chitosan showed broad endothermic peaks at 102°C 
corresponding to its glass transition temperature. NEB-
CS NPs showed both broad and sharp endothermic 
peaks at 102°C and 221°C which corresponds to 
chitosan and Nebivolol respectively which predicts that 
the drug is homogenously dispersed in polymer matrix.  
Particle size, poly dispersity index (PDI) and zeta 
potential of nanoparticles 
The average particle size of the optimized batch (NB-
CS-NPS-1) of nanoparticles was found to be 91 ± 45 
nm. Particle size along with zeta potential (ζ) is the 
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critical factor that affects the biological performance of 
chitosan nanoparticles. The zeta potential of NB-CS-
NPs were found to be + 36.8mV ± 2mV, which indicate 
the physical stability of the formulation. The zeta 
potential also tends to affect particle stability and 
mucoadhesivity.  
Entrapment efficiency 
The entrapment efficiency acts as an important factor 
influencing the drug release, as well as the overall 
efficacy of the formulation.  All the formulations were 
analyzed for entrapment efficiency by using UV-Visible 
spectrophotometer (Shimadzu 1700, Japan) at 285 nm 
and. The entrapment efficiency of the optimized batch 
(NB-CS-NPS-1) of nanoparticles was found to be 70.98. 
In vitro drug release 
 
Figure 2: In vitro drug release 
The In vitro drug release studies were carried out for 
NEB -CS NPs and marketed formulation in PBS 7.4 at 
37 ˚C± 2˚C . The drug release profile of NB-CS-NPs 
showed biphasic release pattern with an initial burst 
release in the first 2 h followed by a controlled release 
over a period of 72 hours and cumulative percentage of 
drug released was obtained to be 71.24 %. 
Accelerated stability studies 
Stability studies were conducted in triplicate for 
optimized formulation which showed slight variations in 
particle size, zeta potential, and drug entrapment during 
3 months of storage. The obtained results indicated no 
significant change in the particle size, zeta potential, and 
drug entrapment during 3 months of storage that ensured 
the stability of nanoparticles. 
CONCLUSION: 
The major challenge in the formulation development is 
the poor aqueous solubility of the new chemical entity 
or existing drug molecules. The formulation of these 
molecules by the application of conventional approaches 
is difficult and associated with several pharmacological 
or therapeutical performance issues. The nanoparticles 
provide a promising approach for enhancing solubility 
and oral bioavailability of water insoluble drugs.  In 
conclusion, formulation of chitosan nanoparticles could 
be an effective strategy for enhancing oral 
bioavailability of nebivolol and other lipophilic drugs 
upon further in vivo pharmacokinetics and 
pharmacodynamics studies.  
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